Cullinan Therapeutics, Inc.
No SEC Form 4 filings for $CGEM in the last 30 days.
Cullinan Therapeutics (Nasdaq: CGEM) reported Q2 2026 results and a corporate update. It said CLN-978 multi-dose data are planned for Q3 2026 (RA) and Q4 2026 (SLE), with Phase 2 expansions starting early 2027. CLN-049 Phase 2 in relapsed/refractory AML is planned for Q3 2026. Cash was $356.0M at June 30, 2026; net loss was $53.7M.
Cullinan Therapeutics, Inc. (CGEM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (B
Cullinan Therapeutics (NASDAQ:CGEM) shares rose 1.6% after the company reported positive FDA feedback from an End-of-Phase 1 meeting for CLN-049, a FLT3xCD3 T cell engager for acute myeloid leukemia. The FDA discussed a Phase 2 plan, with a potentially registrational Phase 2 study starting in Q3 2026 and an update on dose escalation in Q4 2026.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CGEM (Cullinan Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent CGEM coverage spans financial news, earnings and technology.
Near-term catalysts center on FDA-driven Phase 2 initiation for CLN-049 and additional multi-dose data readouts for CLN-978 and velinotamig, supported by a stated cash runway into 2029.
The 8-K adds actionable timing catalysts (FDA-cleared Phase 2 start) plus updated funding runway, which can re-rate near-term probability-weighted value for multiple programs.
FDA feedback supports progression to a potentially registrational Phase 2 design, improving probability-weighted timelines for CLN-049 in relapsed/refractory AML.
FDA feedback supports a potentially registrational Phase 2 path for CLN-049, which can re-rate near-term regulatory probability and timelines.
CGEM’s 2H26 value path is framed around multiple autoimmune data readouts and ongoing regulatory progress (orphan designation).
alphai scores every news story that mentions CGEM with an AI model for sentiment and relevance, and aggregates insider trades from Cullinan Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cullinan Therapeutics (Nasdaq: CGEM) reported Q2 2026 results and a corporate update. It said CLN-978 multi-dose data are planned for Q3 2026 (RA) and Q4 2026 (SLE), with Phase 2 expansions starting early 2027. CLN-049 Phase 2 in relapsed/refractory AML is planned for Q3 2026. Cash was $356.0M at June 30, 2026; net loss was $53.7M.
6 min readCullinan Therapeutics, Inc. (CGEM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (B
5 min readCullinan Therapeutics (NASDAQ:CGEM) shares rose 1.6% after the company reported positive FDA feedback from an End-of-Phase 1 meeting for CLN-049, a FLT3xCD3 T cell engager for acute myeloid leukemia. The FDA discussed a Phase 2 plan, with a potentially registrational Phase 2 study starting in Q3 2026 and an update on dose escalation in Q4 2026.
3 min readCullinan Therapeutics (CGEM) shares rose 2.1% in pre-open after the company said it received constructive FDA feedback from an End-of-Phase 1 meeting for CLN-049. Cullinan plans to start a potentially registrational Phase 2 study in Q3 2026, with dose optimization followed by an expansion cohort, and also plans a Phase 1/2 combo study with venetoclax and azacitidine. Fast Track and Orphan Drug designations apply.
3 min readClear Street names five biotech stocks for 2H 2026 catalysts: MoonLake (MLTX) Buy, $70 target; Cullinan (CGEM) Buy, $46; Zura Bio (ZURA) Buy, $18; Arrivent (AVBP) Buy, $47; Protagonist (PTGX) Buy, $116. It cites planned clinical readouts and regulatory milestones, plus MLTX’s ~$200M offering and AVBP’s up to $250M ATM filing.
7 min readCullinan Therapeutics, Inc. (CGEM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001789972 0001789972 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16,
2 min readH.C. Wainwright has reiterated its Buy rating and $24 price target for Cullinan Oncology (NASDAQ:CGEM) following updated positive data from its Phase 2b REZILIENT1 trial for zipalertinib in NSCLC patients. The stock is currently trading near its 52-week low but is considered undervalued by InvestingPro analysis based on its Fair Value metrics. This comes amidst other recent positive developments, including continued support from analysts despite competing drug approvals.
2 min readCLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases
2 min readTaiho Oncology Inc. and Cullinan Therapeutics Inc. ( NASDAQ:CGEM ) shared new data on Sunday from the central nervous system ( CNS ) involvement cohort of the REZILIENT2 study of zipalertinib for advanced or metastatic non-small cell lung cancer ( NSCLC ) harboring EGFR exon 20 insertion ...
3 min read
